EnBiotix Reports Publication Highlighting Anti-Persister Agent Targeting Antibiotic-Tolerant Infections In Antimicrobial Agents And Chemotherapy
Published: Oct 02, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--EnBiotix, Inc., a product-focused bioengineering company leveraging systems and synthetic biology platforms to combat the global rise of drug-resistant and drug-tolerant bacterial infections, announced today a publication in Antimicrobial Agents & Chemotherapy , a journal of the American Society for Microbiology, detailing data on EBX-001, the Company’s lead product for the treatment of Pseudomonas aeruginosa infections. The paper titled, “An Anti-Persister Strategy for the Treatment of Chronic Pseudomonas aeruginosa Infections,” was co-authored by a team of scientists from Massachusetts General Hospital, Harvard Medical School, the Geisel School of Medicine at Dartmouth and EnBiotix.
“The publication describes translational work related to our lead program, EBX-001, on the combination of tobramycin with an anti-bacterial potentiator for the treatment of chronic, recurrent Pseudomonas infections. We look forward to further development of this program.”
“EnBiotix’s anti-persister platform combines current standard-of-care therapeutics with potentiator molecules to significantly enhance the eradication of persistent drug-tolerant bacteria,” commented Diane Joseph-McCarthy, Ph.D., Vice President of Translational Science at EnBiotix. “The publication describes translational work related to our lead program, EBX-001, on the combination of tobramycin with an anti-bacterial potentiator for the treatment of chronic, recurrent Pseudomonas infections. We look forward to further development of this program.”
Jeffrey D. Wager, M.D., Chairman and CEO of EnBiotix, added, “It is deeply motivating for us at EnBiotix to realize we could offer a substantial therapeutic option to address cystic fibrosis and other serious antibiotic-tolerant infections with this therapy. The results reported in the AAC publication present significant promise for further development of anti-persister treatments, and we are excited to do so with EBX-001 for these indications.”
EnBiotix’s Anti-persister Platform
In response to a variety of stresses including antibiotic treatment, bacteria can enter into a persistent or quasi-dormant state in which they are unresponsive or tolerant to antibiotic treatment. Bacteria in this persistent state are responsible for serious, recurrent infections associated with high morbidity and mortality. EnBiotix’s anti-persister platform utilizes a potentiator molecule to stimulate persisters metabolically to enable uptake of and killing by aminoglycoside antibiotics. Our lead program, EBX-001, combines tobramycin with a metabolite potentiator as a novel inhaled treatment, with broad IP coverage covering the product combination and the indication. In addition to EBX-001, EnBiotix has other combinations in its pipeline that are being developed for the treatment of a variety of Gram-negative infections.
EnBiotix is an engineered antibiotics company deploying novel systems and synthetic biology technologies developed by Prof. James J. Collins, the Termeer Professor of Medical Engineering & Science Professor, Department of Biological Engineering, Massachusetts Institute of Technology. These technologies enable the development of both novel antibiotics and potentiators of existing antibiotics which have the potential to transform their spectrum of activity and resistance profile. With drug-resistant and drug-tolerant infections rapidly becoming a global health crisis, EnBiotix’s robust product pipeline addresses a wide range of acute and chronic infections to significantly impact the lives of patients. www.enbiotix.com